China Medical System Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

China Medical System Holdings şirketinin toplam hissedar öz sermayesi CN¥16.0B ve toplam borcu CN¥1.1B olup, bu da borç-öz sermaye oranını 6.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥18.1B ve CN¥2.2B dir. China Medical System Holdings 'in FAVÖK'ü CN¥1.7B faiz karşılama oranı -12.6 dur. Şirketin CN¥6.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

6.9%

Borç/özkaynak oranı

CN¥1.11b

Borç

Faiz karşılama oranı	-12.6x
Nakit	CN¥6.04b
Eşitlik	CN¥15.97b
Toplam yükümlülükler	CN¥2.18b
Toplam varlıklar	CN¥18.15b

Son finansal sağlık güncellemeleri

Recent updates

Earnings Tell The Story For China Medical System Holdings Limited (HKG:867) As Its Stock Soars 26%

Sep 30

Little Excitement Around China Medical System Holdings Limited's (HKG:867) Earnings

Jul 15

An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 20% Undervalued

May 22

China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year

May 03

We Think Shareholders May Want To Consider A Review Of China Medical System Holdings Limited's (HKG:867) CEO Compensation Package

May 02

China Medical System Holdings' (HKG:867) Shareholders Will Receive A Smaller Dividend Than Last Year

Apr 19

China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year

Mar 29

Not Many Are Piling Into China Medical System Holdings Limited (HKG:867) Stock Yet As It Plummets 35%

Mar 28

China Medical System Holdings Limited's (HKG:867) Share Price Not Quite Adding Up

Dec 21

Is China Medical System Holdings (HKG:867) A Risky Investment?

Dec 04

If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity

Nov 15

China Medical System Holdings (HKG:867) Will Pay A Larger Dividend Than Last Year At CN¥0.342

Aug 31

China Medical System Holdings (HKG:867) Could Easily Take On More Debt

Aug 30

Here's Why We Think China Medical System Holdings (HKG:867) Might Deserve Your Attention Today

Aug 07

We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease

May 14

Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?

Apr 26

An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 47% Undervalued

Feb 05

China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly

Dec 26

If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity

Dec 08

Is China Medical System Holdings (HKG:867) Using Too Much Debt?

Sep 14

China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year

Aug 25

Do China Medical System Holdings' (HKG:867) Earnings Warrant Your Attention?

Aug 15

An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 49% Undervalued

Jul 08

Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?

May 16

Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?

Apr 10

China Medical System Holdings (HKG:867) Is Increasing Its Dividend To HK$0.28

Mar 22

If You Like EPS Growth Then Check Out China Medical System Holdings (HKG:867) Before It's Too Late

Feb 09

Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?

Dec 25

Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?

Nov 10

China Medical System Holdings (HKG:867) Could Easily Take On More Debt

Sep 25

China Medical System Holdings' (HKG:867) Dividend Will Be Increased To HK$0.32

Aug 26

Here's Why We Think China Medical System Holdings (HKG:867) Is Well Worth Watching

Jul 30

An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 33% Undervalued

Jun 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 867 'nin kısa vadeli varlıkları ( CN¥8.8B ) kısa vadeli yükümlülüklerini ( CN¥2.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: 867 şirketinin kısa vadeli varlıkları ( CN¥8.8B ) uzun vadeli yükümlülüklerini ( CN¥128.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 867 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 867 'nin borç/öz sermaye oranı son 5 yılda 15.6% seviyesinden 6.9% seviyesine düştü.

Borç Kapsamı: 867 'nin borcu işletme nakit akışı ( 170.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 867 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Bilanço

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/21 05:21
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

China Medical System Holdings Limited 34 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jessica Li	BofA Global Research
Lok Kwan Chiu	CCB International Securities Limited
Harry He	China Galaxy International Securities (Hong Kong)

China Medical System Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is China Medical System Holdings (HKG:867) A Risky Investment?

China Medical System Holdings (HKG:867) Could Easily Take On More Debt

We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease

China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly

Is China Medical System Holdings (HKG:867) Using Too Much Debt?

Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?

Recent updates

China Medical System Holdings Limited Announces First Prescription for Innovative Drug Lumeblue Issued in China

China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Innovative Drug

China Medical System Holdings Limited Announces New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong

Insufficient new directors

Investor sentiment improves as stock rises 20%

Earnings Tell The Story For China Medical System Holdings Limited (HKG:867) As Its Stock Soars 26%

China Medical System Holdings Limited Announces New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

Founder recently bought HK$3.6m worth of stock

First half dividend of HK$0.16 announced

First half 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.78 in 1H 2023)

China Medical System Holdings Limited Announces Re-Designation of Directors

New minor risk - Profit margin trend

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on About 9 September 2024

China Medical System Holdings Limited Announces NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China

China Medical System Holdings Limited to Report First Half, 2024 Results on Aug 15, 2024

Little Excitement Around China Medical System Holdings Limited's (HKG:867) Earnings

China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection

Now 20% undervalued after recent price drop

Founder recently bought HK$6.8m worth of stock

An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 20% Undervalued

Now 20% undervalued after recent price drop

China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023

China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year

We Think Shareholders May Want To Consider A Review Of China Medical System Holdings Limited's (HKG:867) CEO Compensation Package

Now 21% undervalued after recent price drop

China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China

China Medical System Holdings' (HKG:867) Shareholders Will Receive A Smaller Dividend Than Last Year

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 18%

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year

Final dividend of HK$0.086 announced

Not Many Are Piling Into China Medical System Holdings Limited (HKG:867) Stock Yet As It Plummets 35%

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 38% undervalued after recent price drop

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

China Medical System Holdings Limited's (HKG:867) Share Price Not Quite Adding Up

China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China

China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application (Nda) for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China

Is China Medical System Holdings (HKG:867) A Risky Investment?

If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity

Upcoming dividend of HK$0.34 per share at 5.1% yield

China Medical System Holdings (HKG:867) Will Pay A Larger Dividend Than Last Year At CN¥0.342

First half 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.73 in 1H 2022)

China Medical System Holdings (HKG:867) Could Easily Take On More Debt

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023

China Medical System Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Here's Why We Think China Medical System Holdings (HKG:867) Might Deserve Your Attention Today

China Medical System Holdings Limited Receives Approval from National Medical Products Administration of China for New Drug Application of Diazepam Nasal Spray

National Medical Products Administration of China Approves China Medical System Holdings's New Drug Application of Tildrakizumab Injection under the Brand Name of ILUMETRI

We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease

Upcoming dividend of HK$0.27 per share at 4.5% yield

Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021)

China Medical System Holdings Limited Announces New Drug Application of Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 47% Undervalued

China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly

China Medical System Holdings Limited Announces its Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Obtains Positive Results for its Phase III Clinical Trial in China

If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity

Investor sentiment improved over the past week

Is China Medical System Holdings (HKG:867) Using Too Much Debt?

Upcoming dividend of HK$0.34 per share

China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year

First half 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.66 in 1H 2021)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 15 September 2022